Shoulder Innovations (SI)

Executive Summary

Shoulder Innovations is a publicly traded medical device company revolutionizing shoulder arthroplasty with its patented InSet® Glenoid technology. The company addresses the primary cause of implant failure—aseptic loosening—through a novel inlay fixation approach that enhances implant stability and preserves bone stock. By reducing the risk of revision surgery, the technology aims to improve long-term patient outcomes and lower healthcare costs in both hospital and ambulatory surgical center settings. With its first commercial product gaining traction, Shoulder Innovations is poised to capture a significant share of the growing shoulder replacement market, which is expanding due to an aging population and increasing adoption of outpatient procedures. The company's strong intellectual property portfolio and positive initial clinical feedback position it for accelerated growth. However, as a relatively small player in the orthopedic space, scalability and market penetration remain key challenges. The conviction score reflects the technology's clear clinical advantage and early commercial momentum, tempered by the competitive landscape and execution risk.

Upcoming Catalysts (preview)

• Q1 2026Release of 2-year clinical follow-up data from InSet Glenoid pivotal study80% success
• Q2 2026FDA 510(k) clearance for next-generation instrument set enabling broader surgeon adoption70% success
• Q3 2026Announcement of first major hospital system contract for InSet Glenoid60% success